ESR1 and cancer: A second therapeutic consideration derived from the pathologic characteristics of ER-intermediate cancers is the rate of HER2 positivity, which is higher, suggesting that a subset of these more aggressive tumors would benefit from addition of anti-HER2 targeting treatments, which are clinically available and effective [29,30,31].